about
X-ray structure analyses of photosynthetic reaction center variants from Rhodobacter sphaeroides: structural changes induced by point mutations at position L209 modulate electron and proton transferCrystal structure of SRP19 in complex with the S domain of SRP RNA and its implication for the assembly of the signal recognition particleInduced structural changes of 7SL RNA during the assembly of human signal recognition particleCutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformationsTyramine fragment binding to BACE-1The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activityStructural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexesCrystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulationX-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitorsStructural basis for the cyclophilin A binding affinity and immunosuppressive potency ofE-ISA247 (voclosporin)Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structuresRational design of highly selective spleen tyrosine kinase inhibitors3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsPyrrolopyrazines as selective spleen tyrosine kinase inhibitorsDevelopment of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole leadStrategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinomeDiscovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitorsβ-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's diseaseDevelopment of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical propertiesMapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and XaperonesIdentification of potent and selective cathepsin S inhibitors containing different central cyclic scaffoldsStructure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritisScaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazinesFinding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffoldDiscovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus MonkeysA Real-World Perspective on Molecular DesignStructure and assembly of the spliceosomal snRNPs. Novartis Medal Lecture
P50
Q27630959-C74FAD14-97E7-405F-B30D-615B3E801869Q27639264-0B283730-6C1D-4F06-80FA-4FC56CFC30C2Q27639677-2C9DE0B1-CBB0-4A66-83FD-2B40EB8499BCQ27643867-C6BEC3B3-39A4-4129-BE3A-42762109B2E4Q27649725-FAC17C2F-D364-4719-962B-76C791E934ABQ27652230-2157C36C-65A0-488B-9599-B71E72012376Q27653828-7F4637D1-BA19-40C9-A65C-F60DEBF92878Q27662256-CC06F5A5-CB93-4ABB-9DCF-A7652F928749Q27663588-E1497E8B-59E6-4BE1-943F-7B0AC8DD9835Q27666620-3D5220DB-59A5-4BE4-AE69-F0AA1F1BB7DCQ27666787-8BE37504-0DC0-4287-8FCA-29E7EC733DFFQ27683422-ACA4241B-4012-4BE6-A373-C01C0AE10748Q27683554-4FA78A2C-E3BE-4EE6-A61E-4F6D1F69C30BQ27683820-732EA814-A99A-405A-B260-FFD7050EB67CQ27683828-065E0BF7-06DB-464B-9AD1-B5C38CAABA0AQ27684310-32AD56C6-2592-4D39-A393-45CA53AF10DDQ27684317-497AD4B9-F4C6-4E0F-88E1-E52476A088E9Q27684422-4BA370F0-83A5-4F7E-823C-CDB083010DD1Q27684588-D503572D-063C-4B1B-9202-32CA0B0F8E23Q27684673-E6420F01-5509-49FF-958D-80CA73CD98FFQ27687515-DAE69289-CA2A-4E41-9AFA-B6BCE7B7EEA9Q27690023-6EF23420-23AC-4C35-A9A8-1681452564AAQ27695656-34C2A26F-DEBA-457D-A86B-44873DEE9D9CQ27696302-30E422DD-ADE7-498C-AC95-7473B2E38F6DQ27702203-92A05C98-D834-42F3-8C4D-12B9E51D300CQ27704031-5B87A580-E998-4D84-A18E-8E6FA45A9886Q28189273-3E419C9A-3E2F-4AA5-B4C8-7D96066C7F3D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andreas Kuglstatter
@ast
Andreas Kuglstatter
@en
Andreas Kuglstatter
@es
Andreas Kuglstatter
@nl
Andreas Kuglstatter
@sl
type
label
Andreas Kuglstatter
@ast
Andreas Kuglstatter
@en
Andreas Kuglstatter
@es
Andreas Kuglstatter
@nl
Andreas Kuglstatter
@sl
prefLabel
Andreas Kuglstatter
@ast
Andreas Kuglstatter
@en
Andreas Kuglstatter
@es
Andreas Kuglstatter
@nl
Andreas Kuglstatter
@sl